This study analyzed the effectiveness of pioglitazone (Actos) in patients with prediabetes or type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD). The authors concluded that pioglitazone can significantly improve liver function in these patients.

This study looked at 8 glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of type 2 diabetes (T2D). They found that all 8 were more effective than placebo and there were no significant differences in safety.

This review looked at whether exercise can improve heart rate variability (HRV) for patients with type 2 diabetes (T2D). It found that exercise improved HRV, which indicates better nerve health of the heart.

This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after the first dose.

This study looked at how the Diabeloop system managed exercise for patients with type 1 diabetes (T1D). It found that people using this system did not have more hypoglycemia (dangerously low blood sugar) on days with exercise.

This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients.

This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs.

In this study, the authors evaluated the effectiveness of adding dapagliflozin (Farxiga) to insulin therapy in patients with uncontrolled type 2 diabetes (T2D). The study showed that compared to increasing insulin doses, dapagliflozin improved glucose control while reducing weight and hypoglycemia (dangerously low blood glucose levels) risk.

This study evaluated the addition of linagliptin (Trajenta) to metformin (Glucophage) and lifestyle changes in patients with persistent prediabetes. The authors concluded that adding linagliptin after 12 months of metformin treatment and lifestyle changes improved glucose levels and pancreatic β-cell function in these patients. 

This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects.